CN103864816B - 噻吩并四氢吡啶芳酸醚类化合物、制备方法及其应用 - Google Patents
噻吩并四氢吡啶芳酸醚类化合物、制备方法及其应用 Download PDFInfo
- Publication number
- CN103864816B CN103864816B CN201410090389.3A CN201410090389A CN103864816B CN 103864816 B CN103864816 B CN 103864816B CN 201410090389 A CN201410090389 A CN 201410090389A CN 103864816 B CN103864816 B CN 103864816B
- Authority
- CN
- China
- Prior art keywords
- sffa
- och
- compound
- salt
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 *C(C1)=C(*CCC(C2)[C@](C3)C2CCc2c3cc[s]2)C=C[C@]1C=CC(O)=O Chemical compound *C(C1)=C(*CCC(C2)[C@](C3)C2CCc2c3cc[s]2)C=C[C@]1C=CC(O)=O 0.000 description 2
- OGUWOLDNYOTRBO-UHFFFAOYSA-N C(CNC1)c2c1cc[s]2 Chemical compound C(CNC1)c2c1cc[s]2 OGUWOLDNYOTRBO-UHFFFAOYSA-N 0.000 description 1
- UVYCFZKVZQJBNX-SNAWJCMRSA-N C=C(/C=C/c(cc1)ccc1OCCCN(CC1)CC(C=C2)=C1[IH]2=C)O Chemical compound C=C(/C=C/c(cc1)ccc1OCCCN(CC1)CC(C=C2)=C1[IH]2=C)O UVYCFZKVZQJBNX-SNAWJCMRSA-N 0.000 description 1
- HIADQQISXWIWBW-MDZDMXLPSA-N CC(/C=C/c1cc(OC)c(CCCCN2CC(C=CC3)=C3CC2)cc1)=O Chemical compound CC(/C=C/c1cc(OC)c(CCCCN2CC(C=CC3)=C3CC2)cc1)=O HIADQQISXWIWBW-MDZDMXLPSA-N 0.000 description 1
- JLYLVGHFFZGZCB-UHFFFAOYSA-N CC(C)=C(CCNC)SC=C Chemical compound CC(C)=C(CCNC)SC=C JLYLVGHFFZGZCB-UHFFFAOYSA-N 0.000 description 1
- VMLWKTIRRQGNKF-UHFFFAOYSA-N CCC(CCC(C)OCCN)C(C)O Chemical compound CCC(CCC(C)OCCN)C(C)O VMLWKTIRRQGNKF-UHFFFAOYSA-N 0.000 description 1
- ROAHYZAPHAEWBZ-ZZXKWVIFSA-N OC(/C=C/c(cc1)ccc1OCCN(CC1)Cc2c1[s]cc2)=O Chemical compound OC(/C=C/c(cc1)ccc1OCCN(CC1)Cc2c1[s]cc2)=O ROAHYZAPHAEWBZ-ZZXKWVIFSA-N 0.000 description 1
- DFOOPVDVQVQWPH-UHFFFAOYSA-N OCCN(CC1)Cc2c1[s]cc2 Chemical compound OCCN(CC1)Cc2c1[s]cc2 DFOOPVDVQVQWPH-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明涉及药物化学领域,具体涉及一类噻吩并四氢吡啶芳酸醚类化合物(I)(II)、制备方法,以及含有它们的药物组合物,药效学试验证明本发明的噻吩并四氢吡啶芳酸醚类化合物可用于治疗或预防血栓栓塞性疾病。
Description
技术领域
本发明涉及药物化学领域,具体涉及一类噻吩并四氢吡啶芳酸醚类化合物、制备方法,以及含有它们的药物组合物,本发明的噻吩并四氢吡啶芳酸醚类化合物可用于治疗或预防血栓栓塞性疾病。
背景技术
心脑血管疾病是当今世界上威胁人类身体健康的最严重疾病之一,大多数心脑血管疾病均与血栓形成关系密切相关。血小板聚集是正常凝血机制中的一个关键环节,血小板的黏附、聚集和释放会导致血栓形成。抗血小板聚集药物能够抑制血小板的黏附和聚集,在治疗血栓病中发挥重要作用,一直是人们研究的热点[参见袁明,赵永海,李家明等.丁香酸衍生物的合成及抗血小板聚集活性.中国新药杂志,2012,20(18):1801-1804]。
血栓烷素(TXA2)是花生四烯酸代谢过程中生成的具有强生理活性的产物,研究表明许多心血管疾病的发生与TXA2的过多生成有关。TXA2的生成是通过体内一系列的酶而发挥作用,在这些途径中都需要TXA2合成酶的参与。奥扎格雷(Ozagrel)和达唑氧苯(Dazoxiben)为选择性TXA2合成酶抑制剂,具有很强的抗血小板聚集作用,奥扎格雷临床上主要用于急性脑梗死、冠心病和心绞痛的治疗,达唑氧苯临床上用于心肌梗死和雷诺氏病的治疗。它们的结构特征均为一端为碱性基团,另一端为酸性基团,且末端氮原子与羧基之间的距离在1.0nm左右抗血小板聚集活性最强。发明人前期研究中以奥扎格雷和达唑氧苯为模型化合物,以阿魏酸、川芎嗪为先导物,设计合成了一系列一端为酸性基团,另一端为碱性基团的化合物,药效筛选发现大多数化合物均具有较好的抗血小板聚集活性,其中川芎嗪和阿魏酸的拼合物吡拉格雷对ADP诱导的血小板聚集具有显著的抑制活性,其IC50是奥扎格雷的5.7倍,是阿魏酸川芎嗪盐的192倍(参见李家明,赵永海,马逢时,等.川芎嗪芳酸衍生物的合成及抗血小板聚集活性.有机化学,2008,28(9):1578-1583)。体内抗血小板聚集实验结果显示,以吗啉、哌啶、二甲氨基等脂肪氨基替代咪唑基合成的阿魏酸衍生物,在给药浓度剂量为2mL/kg,浓度为11.99mmol/L下对ADP诱导的家兔血小板聚集均具有很强的抑制作用,其中化合物(E)-3-(3-甲氧基-4-(2-吗啉乙氧基)苯基)丙烯酸的抑制率达91.4%,显著强于阳性对照药奥扎格雷,(李家明,赵永海,钟国琛,等.阿魏酸衍生物的合成及抗血小板聚集活性.药学学报,2011,46(3):305-310)。
噻吩并吡啶类抗血小板药物噻氯匹定、氯吡格雷和普拉格雷能够选择性地抑制二磷酸腺苷(ADP)与其血小板受体的结合,通过继发的ADP介导的糖蛋白GPIIb/IIIa复合物的活化作用抑制血小板聚集。噻氯匹定和氯吡格雷存在的不足是起效时间滞后,不同患者间的血小板抑制作用差异大,它不能适合所有患者---氯吡格雷“抵抗”或弱应答的患者占据相当比例。普拉格雷是对氯吡格雷进行结构改造得到的药品,普拉格雷在肝脏中代谢为活性代谢物更为容易,其活性代谢物能不可逆地抑制血小板P2Y12受体,活性与氯吡格雷活性代谢物相当。但在接受普拉格雷患者中有时可见到严重的出血,风险较大。为了获得更为安全有效的噻吩并吡啶类抗血小板聚集药物,刘登科课题组设计并合成系列噻吩并吡啶类化合物,大多具有较好的抗血小板聚集作用[参见刘颖,岳南,陈芙蓉,等.一类噻吩并吡啶衍生物,其制备方法和用途[P].CN101830911A(2010-09-15);刘登科,刘颖,刘默,等.含噻吩并吡啶的哌嗪类衍生物,其制备方法和用途[P].CN101284838A(2008-10-15)]。
发明内容
本发明以氯吡格雷中关键药效团噻吩并四氢吡啶基作为碱性基团,与阿魏酸等芳酸进行拼合,设计并合成噻吩并四氢吡啶芳酸醚类化合物,药效学试验显示本发明化合物具有TXA2合成酶和血小板P2Y12受体双重抑制作用的药物。
本发明化合物包括通式(I)和通式(II):
其中R1代表H、3-甲氧基或3,5-二甲氧基;R2代表H或4-甲氧基;
n1=1或2;n2=0或1。
本发明的化合物,优先下列任一结构式的化合物:
本发明的化合物其药学上可接受的盐具有同样的药理药效。所述的药学上可接受的盐优选碱金属或碱土金属盐、碱性氨基酸盐、或医药上允许的无机酸或有机酸形成的盐。碱金属盐为钠盐、钾盐;碱土金属盐为钙盐、镁盐;碱性氨基酸盐为精氨酸盐;无机酸盐为盐酸、硫酸、磷酸盐;有机酸盐为马来酸、富马酸、枸橼酸、甲磺酸、对甲苯磺酸、酒石酸、醋酸盐。
本发明的化合物可用下列方法制备:
下面是本发明部分化合物的药效学试验及结果:
普通家兔,雄性,体重1.8-2.0kg,0.38g枸橼酸钠与10mL生理盐水配制成3.8%的枸橼酸钠溶液,用利多卡因局部麻醉,颈动脉插管放血,和枸橼酸钠溶液以9:1混合,以500-800r/min离心10min,取富血小板血浆(PRP),剩余部分以3000r/min离心,取贫血小板血浆(PPP),聚集诱导剂用10ug/mL二磷酸腺苷(ADP)、200ug/mL花生四烯酸(AA)。每管180uLPRP中加入不同浓度的药物10uL,对照组PRP中加入生理盐水10uL,温育3min,然后加入上述不同浓度的诱导剂,用LG-PABER-1型血小板聚集仪检测血小板聚集率。所有实验重复6次,根据各组聚集率平均值与空白组聚集率均值按下列公式计算血小板聚集抑制率。
本发明化合物对AA和ADP诱导的血小板聚集的抑制活性分别见表1和表2。
表1噻吩并四氢吡啶芳酸醚类化合物对AA诱导的血小板聚集的抑制活性
化合物代号 | IC50(mmol/L) | 化合物代号 | IC50(mmol/L) |
SFFA1 | 0.282 | SFFA9 | 0.020 |
SFFA2 | 0.518 | SFFA10 | 1.034 |
SFFA3 | 0.431 | SFFA11 | 86.035 |
SFFA4 | 75.741 | SFFA12 | 156.382 |
SFFA5 | 1.694 | SFFA13 | 0.067 |
SFFA6 | 0.949 | SFFA14 | 0.101 |
SFFA7 | 8.804 | 奥扎格雷钠 | 0.041 |
SFFA8 | 25.704 | 硫酸氢氯吡格雷 | 15.025 |
表2噻吩并四氢吡啶芳酸醚类化合物对ADP诱导的血小板聚集的抑制活性
化合物代号 | IC50(mmol/L) | 化合物代号 | IC50(mmol/L) |
SFFA1 | 271.831 | SFFA9 | 6.937 |
SFFA2 | 0.141 | SFFA10 | 0.224 |
SFFA3 | 0.040 | SFFA11 | 42.002 |
SFFA4 | 0.861 | SFFA12 | 6.466 |
SFFA5 | 0.369 | SFFA13 | 6.429 |
SFFA6 | 19.865 | SFFA14 | 0.255 |
SFFA7 | 0.018 | 奥扎格雷钠 | 0.033 |
SFFA8 | 1.241 | 硫酸氢氯吡格雷 | 7.677 |
上述体外抗血小板聚集实验结果显示,本发明的噻吩并四氢吡啶类化合物中SFFA1,SFFA2、SFFA3、SFFA5、SFFA6、SFFA7、SFFA9、SFFA10、SFFA13、SFFA14对AA诱导的血小板聚集均具有较好的抑制作用,均强于硫酸氢氯吡格雷(可能与氯吡格雷为生物前药,体外抗血小板聚集活性较弱有关),其中SFFA9强于阳性对照药奥扎格雷。本发明化合物中SFFA2,SFFA3、SFFA4、SFFA5、SFFA7、SFFA8、SFFA9、SFFA10、SFFA12、SFFA13、SFFA14对ADP诱导的血小板聚集均具有显著的抑制活性,均强于硫酸氢氯吡格雷(可能与氯吡格雷为生物前药,体外抗血小板聚集活性较弱有关),其中SFFA7强于阳性对照药奥扎格雷。化合物SFFA9和SFFA7显示出较好的药用前景。
本发明还提供了一种治疗或预防心脑血管疾病的的药物组合物,其中含有治疗有效量的通式I或II化合物和药学上可接受的载体。所述药物组合物可以是普通片剂或胶囊、缓释片剂或胶囊、控释片剂或胶囊、口服液、注射剂等制剂学上常规的制剂形式。
一般地,本发明的化合物用于治疗时,人用剂量范围为lmg~1000mg/天。也可根据剂型的不同和疾病严重程度,使用剂量超出该范围。
具体实施方式
实施例1
(E)-3-(4-(3-(6,7-二氢噻吩并[3,2-c]吡啶-5(4H)-基)丙氧基)-3-甲氧基苯基)丙烯酸(SFFA1)的合成
1.1(E)-3-(4-(3-溴丙基)-3-甲氧基苯基)丙烯酸乙酯合成
将1,3-二溴丙烷(15.0g,75.0mmol)、无水碳酸钾10.0g、丁酮75mL加入带有冷凝回流装置的三颈烧瓶中,搅拌,升温至80℃下回流,分批加入阿魏酸乙酯(5.00g,23.0mmol),继续回流6h,TLC[V(石油醚):V(乙酸乙酯)=4:1为展开剂]检测显示反应基本完全。冷却,过滤,用少量乙酸乙酯洗涤滤饼,浓缩,得淡黄色油状物,经硅胶柱分离,得(E)-3-(4-(3-溴丙基)-3-甲氧基苯基)丙烯酸乙酯白色晶体5.10g,收率66.0%,m.p.74.4~75.0℃。
1.2(E)-3-(4-(3-(6,7-二氢噻吩并[3,2-c]吡啶-5(4H)-基)丙氧基)-3-甲氧基苯基)丙烯酸乙酯合成
将4,5,6,7-四氢噻吩并[3,2-c]吡啶盐酸盐(3.80g,11.0mmol)、无水碳酸钾6.0g、氢氧化钠(600mg,15.0mmol)及丁酮75mL加入带有冷凝回流装置的三颈烧瓶中,升温至80℃,回流30min,加入(E)-3-(4-(3-溴丙氧基)-3-甲氧基苯基)丙烯酸乙酯(5.00g,15.0mmol),继续回流6h,TLC[V(石油醚):V(乙酸乙酯)=4:1为展开剂]检测显示反应基本完全。冷却,过滤,用少量乙酸乙酯洗涤滤饼,减压回收溶剂后的淡黄色油状物经硅胶柱分离,得(E)-3-(4-(3-(6,7-二氢噻吩并[3,2-c]吡啶-5(4H)-基)丙氧基)-3-甲氧基苯基)丙烯酸乙酯白色晶体2.50g,收率42.8%,m.p.65.6~67.5℃;1HNMR(CDCl3,400MHz)δ:7.62(d,J=16.0Hz,1H,ArCH=),7.08(d,J=4.0Hz,1H,ThH),7.07-7.05(m,2H,ArH),6.89(d,J=8.4Hz,1H,ArH),6.72(d,J=5.2Hz,1H,ThH),6.30(d,J=16.0Hz,1H,=CH-),4.28(q,J=6.8Hz,2H,CH3CH2O),4.16(t,J=6.4Hz,2H,OCH2CH2CH2N),3.89(s,3H,OCH3),3.59-3.57(m,2H,Py-CH2),2.90-2.88(m,2H,Py-CH2),2.84-2.82(m,2H,Py-CH2),2.74(t,J=6.8Hz,2H,OCH2CH2CH2N),2.17-2.10(m,2H,OCH2CH2CH2N),1.33(t,J=6.8Hz,2H,CH3CH2O);13C-NMR(CDCl3,100MHz)δ:167.2,150.4,149.5,144.5,133.1,132.7,127.5,125.2,123.1,122.5,116.0,112.7,110.1,67.1,60.4,55.9,54.0,52.8,50.7,26.7,24.9,14.4;IR(KBr,cm-1)υ:2952.0,1710.2,1633.8,1593.4,1516.5,1459.8,1259.7,1155.7,1035.9,981.1,943.9,853.1,793.0,731.8;ESI-Mass(+c)forC22H27NO4S:m/z(M++H)402.28。
1.3(E)-3-(4-(3-(6,7-二氢噻吩并[3,2-c]吡啶-5(4H)-基)丙氧基)-3-甲氧基苯基)丙烯酸(SFFA1)的合成
在100mL单颈烧瓶中,依次加入(E)-3-(4-(3-(4H-6,7-二氢噻吩并[3,2-c]吡啶-5(4H)-基)丙氧基)-3-甲氧基苯基)丙烯酸乙酯(2.20g,5.50mmol)、甲醇30mL和氢氧化钠(300mg,7.70mmol)水溶液10mL,50℃下搅拌4h,TLC[V(甲醇):V(氯仿)=1:10为展开剂]检测显示反应基本完全,减压回收甲醇,用3mol/L稀HCl调至pH=4-5,抽滤,水(15mL×3)洗涤,得SFFA1白色固体1.28g,收率64.0%;m.p.213.4~214.9℃,1HNMR(DMSO-d6,400MHz)δ:11.31(s,1H,COOH),7.53(d,J=16.0Hz,1H,ArCH=),7.48(d,J=5.2Hz,1H,ThH),7.33(d,J=1.6Hz,1H,ArH),7.22(dd,J=J=8.4,1.6Hz,1H,ArH),7.02(d,J=8.4Hz,1H,ArH),6.92(d,J=5.2Hz,1H,ThH),6.47(d,J=16.0Hz,1H,=CH-),4.53-4.50(m,1H,Py-CH2),4.25-4.19(m,1H,Py-CH2),4.14(t,J=6.0Hz,2H,OCH2CH2CH2N),3.79(s,3H,OCH3),3.74-3.71(m,1H,OCH2CH2CH2N),3.37-3.25(m,4H,Py-CH2×2),3.11-3.07(m,1H,OCH2CH2CH2N),2.34-2.31(m,2H,OCH2CH2CH2N);13C-NMR(DMSO-d6,100MHz)δ:167.8,149.6,149.1,144.0,131.4,128.2,127.5,125.2,125.1,122.5,116.9,112.9,110.5,66.0,55.6,52.6,50.2,49.1,23.5,21.6;IR(KBr,cm-1)υ:3110.6,2941.9,1703.4,1640.0,1598.0,1516.2,1458.9,1417.1,1271.7,1032.0,980.4,807.6,710.8;ESI-Mass(+c)forC20H23NO4S:m/z(M++H)374.15。
实施例2
(E)-3-(4-(3-(6,7-二氢噻吩并[3,2-c]吡啶-5(4H)-基)乙氧基)-3-甲氧基苯基)丙烯酸(SFFA2)的合成
按实施例1.2,1.3操作得SFFA2类白色固体,m.p.202.4~204.8℃。1HNMR(DMSO-d6,400MHz)δ:11.98(s,1H,COOH),7.54(d,J=15.6Hz,1H,ArCH=),7.49(d,J=4.8Hz,1H,ThH),7.38(d,J=1.6Hz,1H,ArH),7.25(dd,J=J=1.6Hz,8.0Hz,1H,ArH),7.09(d,J=8.0Hz,1H,ArH),6.92(d,J=4.8Hz,1H,ThH),6.50(d,J=16.0Hz,1H,=CH-),4.58-4.56(m,2H,OCH2CH2N),4.41-4.39(m,1H,Py-CH2),3.86(s,3H,OCH3),3.81-3.79(m,1H,Py-CH2),3.67-3.65(m,2H,Py-CH2),3.50-3.48(m,1H,OCH2CH2N),3.39-3.37(m,2H,Py-CH2),3.15-3.11(m,1H,OCH2CH2N);13C-NMR(DMSO-d6,100MHz)δ:167.7,149.3,148.8,143.8,131.3,128.3,128.1,125.1,125.0,122.3,117.4,113.7,110.8,63.9,55.8,53.5,50.9,49.6,21.5;IR(KBr,cm-1)υ:2959.4,1690.8,1591.0,1513.0,1270.1,1021.4,963.0,831.0,800.2,725.7;ESI-Mass(+c)forC19H21NO4S:m/z(M++H)360.15
实施例3
(E)-3-(4-(3-(6,7-二氢噻吩并[3,2-c]吡啶-5(4H)-基)丙氧基)苯基)丙烯酸(SFFA3)的合成
按实施例1.2,1.3操作得SFFA3白色固体,m.p.206.0-207.7℃。1HNMR(DMSO-d6,400MHz)δ:11.43(s,1H,COOH),7.65(d,J=7.6Hz,2H,ArH),7.55(d,J=16.0Hz,1H,ArCH=),7.48-7.46(m,1H,ThH),6.99(d,J=7.6Hz,2H,ArH),6.92-6.90(m,1H,ThH),6.40(d,J=16.0Hz,1H,-CH=),4.15-4.12(m,3H,Py-CH2andOCH2CH2CH2N),3.71-3.99(m,1H,Py-CH2),3.35-3.31(m,4H,Py-CH2×2),3.16-3.14(m,2H,OCH2CH2CH2N),2.30-2.27(m,2H,OCH2CH2CH2N);13C-NMR(DMSO-d6,100MHz)δ:167.8,160.0,143.6,131.4,130.2,129.9,127.0,125.2,125.0,116.6,114.8,65.2,52.3,50.2,49.0,23.6,21.7;IR(KBr,cm-1)υ:2932.9,1703.0,1632.3,1603.8,1512.6,1470.5,1428.4,1256.1,1034.1,987.5,830.9,706.9;ESI-Mass(+c)forC19H21NO3S:m/z(M++H)344.05。
实施例4
(E)-3-(4-(3-(6,7-二氢噻吩并[3,2-c]吡啶-5(4H)-基)乙氧基)苯基)丙烯酸(SFFA4)的合成
按实施例1.2,1.3操作得SFFA4白色固体,m.p.207.8-208.5℃。1HNMR(DMSO-d6,400MHz)δ:11.41(s,1H,COOH),7.69(d,J=8.4Hz,2H,ArH),7.56(d,J=16.0Hz,1H,ArCH=),7.49(d,J=5.2Hz,1H,ThH),7.07(d,J=8.4Hz,2H,ArH),6.94(d,J=5.2Hz,1H,ThH),6.42(d,J=16.0Hz,1H,-CH=),4.56-4.54(m,2H,OCH2CH2N),4.36-4.34(m,1H,Py-CH2),3.82-3.80(m,1H,Py-CH2),3.68-3.66(m,2H,Py-CH2),3.49-3.46(m,1H,OCH2CH2N),3.47-3.46(m,2H,Py-CH2),3.25-3.24(m,1H,OCH2CH2N);13C-NMR(DMSO-d6,100MHz)δ:167.8,159.1,143.5,131.3,129.9,128.0,127.6,125.2,125.1,117.0,115.1,62.5,53.6,50.7,49.6,21.6;IR(KBr,cm-1)υ:2944.7,1695.2,1641.7,1603.5,1513.3,1455.1,1424.0,1253.7,1016.7,982.8,832.8,733.0;ESI-Mass(+c)forC18H19NO3S:m/z(M++H)329.99。
实施例5
4-(3-(6,7-二氢噻吩并[3,2-c]吡啶-5(4H)-基)丙氧基)-3-甲氧基苯甲酸(SFFA5)的合成
按实施例1.2,1.3操作得SFFA5类白色固体,m.p.228.4-230.2℃。1HNMR(DMSO-d6,400MHz)δ:11.37(s,1H,COOH),7.57(dd,J=J=8.4,2.0Hz,1H,ArH),7.48(d,J=5.2Hz,1H,ThH),7.46(d,J=2.0Hz,1H,ArH),7.08(d,J=8.4Hz,1H,ArH),6.92(d,J=5.2Hz,1H,ThH),4.53-4.50(m,1H,Py-CH2),4.24-4.22(m,1H,Py-CH2),4.18(t,J=6.0Hz,2H,OCH2CH2CH2N),3.79(s,3H,OCH3),3.75-3.72(m,1H,OCH2CH2CH2N),3.38-3.34(m,4H,Py-CH2×2),3.25-312(m,1H,OCH2CH2CH2N),2.36-2.35(m,2H,OCH2CH2CH2N);13C-NMR(DMSO-d6,100MHz)δ:172.2,156.7,153.6,136.6,133.5,130.4,130.3,128.6,128.3,117.5,117.3,71.3,60.7,57.7,55.4,54.3,28.7,26.8;IR(KBr,cm-1)υ:3085.7,2932.7,1703.0,1592.3,1513.8,1468.0,1268.9,1033.9,983.3,728.6,700.0;ESI-Mass(+c)forC18H21NO4S:m/z(M++H)348.13。
实施例6
4-(3-(6,7-二氢噻吩并[3,2-c]吡啶-5(4H)-基)乙氧基)-3-甲氧基苯甲酸(SFFA6)的合成
按实施例1.2,1.3操作得SFFA6类白色固体,m.p.190.8-192.5℃。1HNMR(DMSO-d6,400MHz)δ:11.42(s,1H,COOH),7.58(d,J=8.4Hz,1H,ArH),7.50-7.46(m,2H,ThHandArH),7.15(d,J=8.4Hz,1H,ArH),6.93(d,J=4.8Hz,1H,ThH),4.58-4.52(m,3H,Py-CH2andOCH2CH2N),4.41-4.39(m,1H,Py-CH2),3.86(s,3H,OCH3),3.69-3.67(m,2H,Py-CH2),3.51-3.37(m,2H,OCH2CH2N),3.24-3.16(m,2H,Py-CH2);13C-NMR(DMSO-d6,100MHz)δ:166.9,150.7,148.6,131.3,128.1,125.2,125.1,124.0,123.0,112.8,112.2,63.8,55.7,53.5,51.0,49.6,21.5;IR(KBr,cm-1)υ:2947.9,1703.9,1596.1,1514.2,1454.2,1363.8,1029.5,997.9,764.5,720.5;ESI-Mass(+c)forC17H19NO4S:m/z(M++H)334.03。
实施例7
4-(3-(6,7-二氢噻吩并[3,2-c]吡啶-5(4H)-基)丙氧基)-3,5-二甲氧基苯甲酸(SFFA7)的合成
按实施例1.2,1.3操作得SFFA7白色固体,m.p.247.6-249.3℃。1HNMR(DMSO-d6,400MHz)δ:11.29(s,1H,COOH),7.48(d,J=4.8Hz,1H,ThH),7.25(s,2H,ArH),6.93(d,J=4.8Hz,1H,ThH),4.31-4.29(m,2H,Py-CH2),4.03(t,J=5.2Hz,2H,OCH2CH2CH2N),3.84-3.80(m,7H,OCH3×2andOCH2CH2CH2N),3.41-38(m,3H,Py-CH2andOCH2CH2CH2N),3.15-3.13(m,2H,Py-CH2),2.18-2.16(m,2H,OCH2CH2CH2N);13C-NMR(DMSO-d6,100MHz)δ:166.8,152.7,139.8,131.4,126.2,125.2,125.0,106.3,70.0,55.9,52.7,50.3,49.0,24.5,21.7;IR(KBr,cm-1)υ:2945.7,1702.9,1594.2,1507.8,1460.3,1414.5,1257.0,1030.2,839.1,762.8,724.2;ESI-Mass(+c)forC19H23NO5S:m/z(M++H)378.12。
实施例8
4-(3-(6,7-二氢噻吩并[3,2-c]吡啶-5(4H)-基)乙氧基)-3,5-二甲氧基苯甲酸(SFFA8)的合成
按实施例1.2,1.3操作得SFFA8类白色固体,m.p.192.8-194.6℃。1HNMR(DMSO-d6,400MHz)δ:7.27(d,J=5.2Hz,1H,ThH),7.24(s,2H,ArH),6.80(d,J=5.2Hz,1H,ThH),4.10(t,J=5.6Hz,2H,OCH2CH2N),3.82(s,6H,OCH3×2),3.62-3.60(m,2H,Py-CH2),2.87-2.83(m,4H,Py-CH2andOCH2CH2N),2.80-2.79(m,2H,Py-CH2);13C-NMR(DMSO-d6,100MHz)δ:167.1,152.6,140.1,134.0,132.6,126.5,125.4,122.9,106.4,70.7,56.4,55.9,52.5,50.6,24.9;IR(KBr,cm-1)υ:2936.9,1707.8,1593.6,1502.5,1457.0,1412.5,1316.4,1049.5,1005.7,833.3,721.4;ESI-Mass(+c)forC18H21NO5S:m/z(M++H)364.02。
实施例9
4-(3-(6,7-二氢噻吩并[3,2-c]吡啶-5(4H)-基)丙氧基)-苯甲酸(SFFA9)的合成
按实施例1.2,1.3操作得SFFA9类白色固体,m.p.222.1-223.9℃。1HNMR(DMSO-d6,400MHz)δ:10.80(s,1H,COOH),7.90(d,J=8.4Hz,2H,ArH),7.47(d,J=4.8Hz,1H,ThH),7.03(d,J=8.4Hz,2H,ArH),6.91(d,J=4.8Hz,1H,ThH),4.20-4.18(m,1H,Py-CH2),4.17(t,J=5.2Hz,2H,OCH2CH2CH2N),3.35-3.34(m,1H,Py-CH2),3.33-3.19(m,4H,Py-CH2×2),3.12-3.10(m,2H,OCH2CH2CH2N),2.27-2.23(m,2H,OCH2CH2CH2N);13C-NMR(DMSO-d6,100MHz)δ:167.0,162.1,132.7,132.5,131.3,125.3,123.3,123.0,114.2,65.9,53.2,52.0,50.1,25.7,24.2;IR(KBr,cm-1)υ:3090.4,2853.1,1697.0,1606.2,1512.2,1430.3,1263.1,1036.5,883.9,840.8,768.1;ESI-Mass(+c)forC17H19NO3S:m/z(M++H)318.12。
实施例10
4-(3-(6,7-二氢噻吩并[3,2-c]吡啶-5(4H)-基)乙氧基)-苯甲酸(SFFA10)的合成
按实施例1.2,1.3操作得SFFA10类白色固体,m.p.207.6-209.4℃。1HNMR(DMSO-d6,400MHz)δ:11.63(s,1H,COOH),7.93(d,J=7.6Hz,2H,ArH),7.48(d,J=4.0Hz,1H,ThH),7.12(d,J=7.6Hz,2H,ArH),6.94(d,J=4.0Hz,1H,ThH),4.60-4.58(m,2H,OCH2CH2N),4.53-4.51(m,1H,Py-CH2),4.36-4.34(m,1H,Py-CH2),3.82-3.80(m,1H,OCH2CH2N),3.69-3.67(m,2H,Py-CH2),3.50-3.48(m,1H,OCH2CH2N)),3.26-3.14(m,2H,Py-CH2);13C-NMR(DMSO-d6,100MHz)δ:166.9,161.8,132.9,132.1,131.3,125.3,123.9,123.3,114.4,64.6,54.7,51.8,50.2,23.4;IR(KBr,cm-1)υ:2950.9,1681.3,1607.2,1509.6,1469.9,1425.3,1247.8,1023.0,973.0,841.2,727.0;ESI-Mass(-c)forC17H19NO3S:m/z(M++H)302.26。
实施例11
(E)-3-(3-(3-(6,7-二氢噻吩并[3,2-C]吡啶-5(4H)-基)乙氧基)-4-甲氧基苯基)丙烯酸(SFFA11)的合成
按实施例1.2,1.3操作得SFFA11类白色固体,m.p.207.8-208.5℃,1HNMR(DMSO-d6,400MHz)δ:11.87(s,1H,COOH),7.54(d,J=16.0Hz,1H,ArCH=),7.51(d,J=5.2Hz,1H,ThH),7.48(s,1H,ArH),7.29(d,J=8.4Hz,1H,ArH),7.05(d,J=8.4Hz,1H,ArH),6.93(d,J=5.2Hz,1H,ThH),6.50(d,J=16.0Hz,1H,-CH=),4.58-4.56(m,2H,OCH2CH2N),4.12-4.39(m,1H,Py-CH2),3.84(s,3H,OCH3),3.80-3.78(m,1H,Py-CH2),3.67-3.65(m,2H,Py-CH2),3.51-3.49(m,1H,OCH2CH2N),3.40-3.37(m,2H,Py-CH2),3.27-3.16(m,1H,OCH2CH2N);13C-NMR(DMSO-d6,100MHz)δ:167.8,151.0,147.1,143.8,131.3,128.1,127.1,125.2,125.1,123.9,117.0,112.4,111.9,63.9,55.8,53.5,50.9,49.6,21.5;IR(KBr,cm-1)υ:3050.0,1712.0,1635.0,1601.1,1515.4,1373.1,1265.3,1024.2;984.2,828.5,711.6;ESI-Mass(+c)forC19H21NO4S:m/z(M++H)360.04。
实施例12
(E)-3-(3-(3-(6,7-二氢噻吩并[3,2-C]吡啶-5(4H)-基)丙氧基)-4-甲氧基苯基)丙烯酸(SFFA12)的合成
按实施例1.2,1.3操作得SFFA12类白色固体,m.p.206.0-207.7℃,1HNMR(DMSO-d6,400MHz)δ:11.07(s,1H,COOH),7.52(d,J=16.0Hz,1H,ArCH=),7.49(d,J=5.6Hz,1H,ThH),7.37(s,1H,ArH),7.24(d,J=8.0Hz,1H,ArH),7.00(d,J=8.0Hz,1H,ArH),6.93(d,J=5.6Hz,1H,ThH),6.46(d,J=16.0Hz,1H,-CH=),4.56-4.52(m,1H,Py-CH2),4.25-4.20(m,1H,Py-CH2),4.15-4.13(m,2H,OCH2CH2CH2N),3.77(s,3H,OCH3),3.38-3.36(m,4H,Py-CH2×2),3.28-3.24(m,1H,OCH2CH2CH2N),3.17-3.13(m,1H,OCH2CH2CH2N),2.31-2.29(m,2H,OCH2CH2CH2);13C-NMR(DMSO-d6,100MHz)δ:167.8,150.9,147.8,144.0,131.3,128.2,127.0,125.2,125.1,123.1,116.8,111.8,111.7,66.1,55.5,52.6,50.1,49.0,23.6,21.6;IR(KBr,cm-1)υ:2937.6,1683.3,1626.0,1509.4,1396.6,1257.6,1012.4,978.1,834.0,741.8;ESI-Mass(+c)forC20H23NO4S:m/z(M++H)374.15。
实施例13
3-(3-(6,7-二氢噻吩并[3,2-c]吡啶-5(4H)-基)丙氧基)-4-甲氧基苯甲酸(SFFA13)的合成
按实施例1.2,1.3操作得SFFA13白色固体,m.p.219.3-221.2℃,1HNMR(DMSO-d6,400MHz)δ:11.34(s,1H,COOH),7.59(d,J=7.6Hz,1H,ArH),7.48-7.44(m,2H,ThHandArH),7.07(d,J=7.6Hz,1H,ArH),6.93-6.91(m,1H,ThH),4.51-4.49(m,1H,Py-CH2),4.24-4.20(m,1H,Py-CH2),4.13-4.10(m,2H,OCH2CH2CH2N),3.82(s,3H,OCH3),3.78-3.76(m,1H,OCH2CH2CH2N),3.39-3.35(m,4H,Py-CH2×2),3.12-3.10(m,1H,OCH2CH2CH2N),2.33-2.30(m,2H,OCH2CH2CH2N);13C-NMR(DMSO-d6,100MHz)δ:167.0,152.7,147.2,131.3,128.2,125.2,125.1,123.6,122.9,113.4,111.2,66.0,55.7,52.5,50.1,49.0,23.6,21.6;IR(KBr,cm-1)υ:3080.4,2958.2,1691.1,1593.1,1513.8,1431.3,1267.6,1021.8,831.9,769.9,726.9;ESI-Mass(+c)forC18H21NO4S:m/z(M++H)348.03。
实施例14
3-(3-(6,7-二氢噻吩并[3,2-c]吡啶-5(4H)-基)乙氧基)-4-甲氧基苯甲酸(SFFA14)的合成
按实施例1.2,1.3操作得SFFA14白色固体,m.p.236.2-238.0℃,1HNMR(DMSO-d6,400MHz)δ:11.58(s,1H,COOH),7.64(d,J=8.4Hz,1H,ArH),7.54(s,1H,ArH),7.49(d,J=5.2Hz,1H,ThH),7.12(d,J=8.4Hz,1H,ArH),6.93(d,J=5.2Hz,1H,ThH),4.61-4.55(m,3H,Py-CH2andOCH2CH2N),4.41-4.38(m,1H,Py-CH2),3.88(s,3H,OCH3),3.68-3.66(m,2H,Py-CH2),3.51-3.37(m,2H,OCH2CH2N),3.24-3.16(m,2H,Py-CH2);13C-NMR(DMSO-d6,100MHz)δ:166.9,152.9,146.5,131.3,128.1,125.2,125.1,124.3,123.0,114.2,111.4,63.9,55.9,53.7,51.0,49.6,21.6;IR(KBr,cm-1)υ:3021.5,2930.1,1706.4,1597.5,1518.5,1434.0,1265.3,1028.0,995.2,834.3,725.7;ESI-Mass(+c)forC17H19NO4S:m/z(M++H)334.02。
Claims (5)
1.通式I或II的噻吩并四氢吡啶芳酸醚化合物或其药学上可接受的盐:
其中R1代表H、3-甲氧基或3,5-二甲氧基;R2代表H或4-甲氧基;
n1=1或2;n2=0或1。
2.权利要求1的化合物或其药学上可接受的盐,是下列任一结构的化合物或其药学上可接受的盐:
3.权利要求1的化合物或其药学上可接受的盐,其药学上可接受的盐选自钠盐、钾盐、钙盐、镁盐、精氨酸盐、盐酸盐、硫酸盐、磷酸盐、马来酸盐、富马酸盐、枸橼酸盐、甲磺酸盐、对甲苯磺酸盐、酒石酸盐或醋酸盐。
4.权利要求1的化合物或其药学上可接受的盐用于制备治疗或预防血小板聚集疾病的药物的用途。
5.一种药物组合物,其中含有权利要求1的化合物或其药学上可接受的盐和药学上可接受的载体。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410090389.3A CN103864816B (zh) | 2014-03-12 | 2014-03-12 | 噻吩并四氢吡啶芳酸醚类化合物、制备方法及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410090389.3A CN103864816B (zh) | 2014-03-12 | 2014-03-12 | 噻吩并四氢吡啶芳酸醚类化合物、制备方法及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103864816A CN103864816A (zh) | 2014-06-18 |
CN103864816B true CN103864816B (zh) | 2016-06-15 |
Family
ID=50903883
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410090389.3A Active CN103864816B (zh) | 2014-03-12 | 2014-03-12 | 噻吩并四氢吡啶芳酸醚类化合物、制备方法及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103864816B (zh) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101830911A (zh) * | 2010-06-11 | 2010-09-15 | 天津药物研究院 | 一类噻吩并吡啶衍生物、其制备方法和用途 |
-
2014
- 2014-03-12 CN CN201410090389.3A patent/CN103864816B/zh active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101830911A (zh) * | 2010-06-11 | 2010-09-15 | 天津药物研究院 | 一类噻吩并吡啶衍生物、其制备方法和用途 |
Non-Patent Citations (2)
Title |
---|
噻吩并[3,2-c]吡啶类衍生物的研究进展;袁媛等;《广州化工》;20130731;第41卷(第13期);25-29页 * |
川芎嗪芳酸衍生物的合成及抗血小板聚集活性;李家明等;《有机化学》;20081231;第28卷(第9期);1578-1583页 * |
Also Published As
Publication number | Publication date |
---|---|
CN103864816A (zh) | 2014-06-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN106470975B (zh) | 多环氨基甲酰基吡啶酮化合物的合成 | |
CN106831722B (zh) | 稠合杂环化合物、其制备方法、药物组合物和用途 | |
AU2021203650A1 (en) | Chemical compounds | |
ES2441958T3 (es) | Moduladores de benzofuro- y benzotienopirimidina del receptor de histamina H4 | |
JP6469092B2 (ja) | イミダゾリジンジオン化合物及び薬物組成物 | |
CN106518946A (zh) | 磺酰脲衍生物、其药物组合物及应用 | |
CA3050853A1 (en) | Heterocyclic spiro compounds as magl inhibitors | |
CN106083978A (zh) | 磺酰基氨基羰基衍生物、其药物组合物及应用 | |
UA121775C2 (uk) | 1,1,1-трифтор-3-гідроксипропан-2-ілкарбаматні похідні та 1,1,1-трифтор-4-гідроксибутан-2-ілкарбаматні похідні як інгібітори magl | |
CN105916855A (zh) | 作为酪蛋白激酶1d/e抑制剂的取代的4,5,6,7-四氢吡唑并[1,5-a]吡嗪衍生物 | |
BRPI0720859A2 (pt) | Derivados de isoquinolina e isoquinolinona substituídos com cicloalquilamina | |
WO2020216190A1 (zh) | 一种喹唑啉化合物及其在医药上的应用 | |
CN102056933B (zh) | 作为白三烯a4水解酶调节剂的噻唑并吡啶-2-基氧基-苯基和噻唑并吡嗪-2-基氧基-苯基胺类 | |
CN102131784A (zh) | 作为rho激酶抑制剂的取代的异喹啉和异喹啉酮 | |
CN109843872A (zh) | 作为ido抑制剂和/或ido-hdac双重抑制剂的多环化合物 | |
AU2014342593B2 (en) | N-(1-hydroxy-3-(pyrrolidinyl)propan-2-yl)pyrrolidine-3-carboxamide derivatives as glucosylceramide synthase inhibitors | |
EP3766882A1 (en) | Phthalazine isoxazole alkoxy derivatives, preparation method thereof, pharmaceutical composition and use thereof | |
CN106467495A (zh) | 哒嗪酮类化合物、其制备方法、药物组合物及用途 | |
JP2018510918A (ja) | A2b拮抗薬としてのキサンチン置換アルキニルカルバメート/逆カルバメート | |
CN105524045A (zh) | 四环类间变性淋巴瘤激酶抑制剂 | |
CN102459251B (zh) | 作为白三烯a4水解酶的调节剂的具有两个稠合双环杂芳基部分的化合物 | |
CN103864816B (zh) | 噻吩并四氢吡啶芳酸醚类化合物、制备方法及其应用 | |
EP3083624B1 (en) | Tetrahydro-tetrazolo[1,5-a]pyrazines as ror-gamma inhibitors | |
EP2740458B1 (en) | Packaging comprising forms of sodium salt of 4-tert-butyl-N-[4-chloro-2-(1-oxy-pyridine-4-carbonyl)-phenyl]-benzenesulfonamide | |
CN110818704A (zh) | 螺桥环化合物、其药物组合物及其用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CP01 | Change in the name or title of a patent holder |
Address after: 230038 No. 70 Meishan Road, Hefei City, Anhui Province Co-patentee after: Hefei Medical and Pharmaceutical Co., Ltd. Patentee after: Anhui University of Chinese Medicine Address before: 230038 No. 70 Meishan Road, Hefei City, Anhui Province Co-patentee before: Hefei Yigong Medicine Co., Ltd. Patentee before: Anhui University of Chinese Medicine |
|
CP01 | Change in the name or title of a patent holder |